Literature DB >> 11755293

Progression of human aortic valve stenosis is associated with tenascin-C expression.

Jari Satta1, Jukka Melkko, Raimo Pöllänen, Juha Tuukkanen, Paavo Pääkkö, Pasi Ohtonen, Ari Mennander, Ylermi Soini.   

Abstract

OBJECTIVES: We sought to assess tenascin-C (TN-C) expression and its possible pathobiological impact in human aortic valve stenosis.
BACKGROUND: Tenascin-C, a large extracellular matrix glycoprotein, has lately been increasingly connected to cardiovascular pathologies. As TN-C is a multifunctional protein implicated in cell proliferation, migration and differentiation, we investigated the pattern of its expression in diseased human aortic valves.
METHODS: Fifty-five tricuspid, non-rheumatic stenotic aortic valves were collected from patients undergoing aortic valve replacement, and the controls consisted of four normal valves from individuals who had suffered traumatic death and one from a patient operated on because of a noncalcified purely regurgitant valve. A monoclonal mouse antibody to human TN-C (143DB7) was used as the primary antibody in immunostaining. To study the source of TN-C messenger RNA synthesis, some tissue samples were also examined using in situ hybridization. In order to identify smooth muscle cell differentiation, commercially available antibodies against alpha-smooth muscle actin were used, and immunophenotypic analysis of inflammatory cells was carried out by using the monoclonal mouse antibodies UCHL-1, L26 and PGM-1.
RESULTS: In normal valves, TN-C expression was associated with the basement membrane beneath the endothelial cells, whereas stenotic valves showed no such expression but rather immunoreactivity in the deeper layers of the valves. This reactivity was associated with the characteristics typical of the stenosing process and the increased mechanical loading caused by hypertension.
CONCLUSIONS: We hypothesize that the overexpression of TN-C in stenotic human aortic valves may emphasize that this disease is an active rather than a degenerative process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11755293     DOI: 10.1016/s0735-1097(01)01705-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  20 in total

1.  Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins.

Authors:  D Skowasch; S Schrempf; C J Preusse; J A Likungu; A Welz; B Lüderitz; G Bauriedel
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

Review 2.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 3.  Calcific aortic valve stenosis: methods, models, and mechanisms.

Authors:  Jordan D Miller; Robert M Weiss; Donald D Heistad
Journal:  Circ Res       Date:  2011-05-27       Impact factor: 17.367

4.  Endocardial Brg1 disruption illustrates the developmental origins of semilunar valve disease.

Authors:  Brynn N Akerberg; Maithri L Sarangam; Kryn Stankunas
Journal:  Dev Biol       Date:  2015-06-20       Impact factor: 3.582

5.  Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents.

Authors:  Daihiko Hakuno; Naritaka Kimura; Masatoyo Yoshioka; Makio Mukai; Tokuhiro Kimura; Yasunori Okada; Ryohei Yozu; Chisa Shukunami; Yuji Hiraki; Akira Kudo; Satoshi Ogawa; Keiichi Fukuda
Journal:  J Clin Invest       Date:  2010-06-14       Impact factor: 14.808

6.  Pathogenesis of aortic stenosis: not just a matter of wear and tear.

Authors:  Aaron L Sverdlov; Doan Tm Ngo; Matthew J Chapman; Onn Akbar Ali; Yuliy Y Chirkov; John D Horowitz
Journal:  Am J Cardiovasc Dis       Date:  2011-07-28

7.  Synergistic effects of cyclic strain and Th1-like cytokines on tenascin-C production by rheumatic aortic valve interstitial cells.

Authors:  L Jiang; X F Wei; D H Yi; P Xu; H Liu; Q Chang; S M Yang; Z F Li; H B Gao; G J Hao
Journal:  Clin Exp Immunol       Date:  2008-11-20       Impact factor: 4.330

Review 8.  Calcific aortic stenosis.

Authors:  Brian R Lindman; Marie-Annick Clavel; Patrick Mathieu; Bernard Iung; Patrizio Lancellotti; Catherine M Otto; Philippe Pibarot
Journal:  Nat Rev Dis Primers       Date:  2016-03-03       Impact factor: 52.329

9.  Inhibition of Aortic Valve Calcification by Local Delivery of Zoledronic Acid-an Experimental Study.

Authors:  Andreas Synetos; Konstantinos Toutouzas; Maria Drakopoulou; Iosif Koutagiar; George Benetos; Rafail Kotronias; Nikolaos Anousakis-Vlachochristou; George Latsios; Antonis Karanasos; George Agrogiannis; Marinos Metaxas; Konstantinos Stathogiannis; Aggelos Papanikolaou; Alexandros Georgakopoulos; Nikoleta Pianou; Eleftherios Tsiamis; Efstratios Patsouris; Apostolos Papalois; Dennis Cokkinos; Constantinos Anagnostopoulos; Dimitrios Tousoulis
Journal:  J Cardiovasc Transl Res       Date:  2018-03-26       Impact factor: 4.132

Review 10.  Aortic valve stenosis and arterial hypertension: a synopsis in 2013.

Authors:  Vasiliki Katsi; Maria Marketou; Manolis S Kallistratos; Thomas Makris; Athanasios J Manolis; Dimitris Tousoulis; Christodoulos Stefanadis; Panos Vardas; Ioannis Kallikazaros
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.